Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1
- 1 September 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (17) , 1525-1536
Abstract
The diagnosis, staging, and management of renal cell carcinoma (RCC) are reviewed. The mechanism, pharmacokinetics, toxicity, clinical activity, and application of molecularly targeted agents in RCC are emphasized. RCC is the eighth most commonly diagnosed malignancy in the United States. The most common signs and symptoms are gross hematuria, flank pain, and the presence of a flank mass. Localized disease is found in about 55% of patients, 19% of patients have locally advanced disease, and 20% of patients have metastatic disease. Surgical resection is the mainstay of therapy for stage I-III RCC. The pharmacotherapy of RCC is undergoing significant change. Standard therapy used to include the cytokines interferon alfa and aldesleukin. High-dose aldesleukin is used to treat select patients. Its major value is the durability of responses in the few patients who achieve a complete remission. However, cytokines have been largely displaced by sorafenib tosylate, sunitinib malate, and temsirolimus due to their lower rates of toxicity and positive effects on progression-free survival. Bevacizumab has also shown activity in patients with advanced disease. Estimated five-year survival rates for patients with RCC are 89.6% for localized disease, 60.8% for regional disease, and 9.5% for patients with distant metastases. Studies are currently under way to assess the activity of combinations of available agents and new targeted agents as adjuvant therapy and for the management of advanced RCC. The options available for the management of advanced RCC have expanded considerably in the past five years with the advent of molecularly targeted therapies.Keywords
This publication has 50 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell CarcinomaOncology, 2007
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Laparoscopic partial nephrectomy for cancer: techniques and outcomesInternational braz j urol, 2005
- Prognostic Factors for Survival of Patients with Stage IV Renal Cell CarcinomaClinical Cancer Research, 2004
- Cancer and Leukemia Group B 90206Clinical Cancer Research, 2004
- Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, 2004
- Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized TrialJournal of Clinical Oncology, 2003
- Subcutaneous interleukin‐2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin‐2 and interferon αCancer, 2002
- Recombinant interleukin-2 in metastatic renal cell carcinoma—A European multicentre phase II studyEuropean Journal of Cancer and Clinical Oncology, 1991